Treatment of Calciphylaxis in CKD: A Systematic Review and Meta-analysis.
Suwasin Udomkarnjananun, Kitravee Kongnatthasate, Kearkiat Praditpornsilpa...
https://pubmed.ncbi.nlm.nih.gov/30775620/Actively Recruiting
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2026-03-04
9
Participants Needed
1
Research Sites
52 weeks
Total Duration
This trial focuses on patients with calciphylaxis, a rare and severe condition characterized by extremely painful skin lesions caused by reduced blood flow. The disease often leads to serious infections and has a high death rate, especially among dialysis patients. Researchers are studying whether treatment with human amniotic-derived mesenchymal stem cells hAMSCs can help these patients by addressing wound healing and related complications. Participants receive hAMSC therapy through two methods intravenous infusion and local injection. The infusion involves doses of 1.0 x 106 cells per kilogram, given three times in the first month and then once every four weeks for a total of eight doses over six months. Local injections are administered to the wound area concurrently, with a dose of 2.0 x 104 cells per square centimeter. Treatment duration may be adjusted based on each patients condition. Throughout the study, participants will be monitored for wound healing, pain levels, quality of life, infection, and survival for up to one year. The research includes regular assessments to track these outcomes and ensure safety. This study aims to better understand how hAMSC therapy affects calciphylaxis and its symptoms over time.
CONDITIONS
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
N
Ningning Wang, Professor
L
Lianju Qin, Professor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The First Affiliated Hospital with Nanjing Medical University
Lead Sponsor
Westlake University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 6 months with 8 doses administered over this period, treatment may end earlier or be extended based on clinical condition.
Participants receive human amniotic-derived mesenchymal stem cell therapy through intravenous infusions and local injections to treat calciphylaxis wounds.
8 visits for intravenous infusion and local injection over 6 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Suwasin Udomkarnjananun, Kitravee Kongnatthasate, Kearkiat Praditpornsilpa...
https://pubmed.ncbi.nlm.nih.gov/30775620/Daoxu Wu, Shijiu Lu, Jiaying Hu...
https://pubmed.ncbi.nlm.nih.gov/40097288/Aisha Naeem, Nikita Gupta, Usra Naeem...
https://pubmed.ncbi.nlm.nih.gov/35412950/Deepak Baby, Meenakshi Upadhyay, M Derick Joseph...
https://pubmed.ncbi.nlm.nih.gov/31681640/Lianju Qin, Jing Zhang, Yujie Xiao...
https://pubmed.ncbi.nlm.nih.gov/35142858/Ningning Wang, Andrea Angioi, Nicolas Hanset...
https://pubmed.ncbi.nlm.nih.gov/39234636/Sagar U Nigwekar, Ravi Thadhani, Vincent M Brandenburg
https://pubmed.ncbi.nlm.nih.gov/29719190/José-Vicente Torregrosa, Ana Sánchez-Escuredo, Xoana Barros...
https://pubmed.ncbi.nlm.nih.gov/24075020/Ting Peng, Ling Zhuo, Ying Wang...
https://pubmed.ncbi.nlm.nih.gov/28603903/H Seethapathy, V M Brandenburg, S Sinha...
https://pubmed.ncbi.nlm.nih.gov/30304522/The First Affiliated Hospital with Nanjing Medical University
Lead Sponsor
Westlake University
Collaborating Sponsor